Scientific Opinion on the substantiation of health claims related to Bifidobacterium animalis ssp. lactis Bb-12 and immune defence against pathogens (ID 863), decreasing potentially pathogenic gastro-intestinal microorganisms (ID 866), “natural immune function” (ID 924), reduction of symptoms of inflammatory bowel conditions (ID 1469) and maintenance of normal blood LDL-cholesterol concentrations (ID 3089) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

Bifidobacterium animalis ssp. lactis Bb-12, pathogens, microorganisms, LDL-cholesterol, immune, inflammation, health claims
First published in the EFSA Journal
8 April 2011
12 November 2010
Scientific Opinion

Competing interests: One member of the Panel did not participate in the discussion on the subject referred to above because of potential conflicts of interest identified in accordance with the EFSA policy on declarations of interests.


No abstract available

Panel members at the time of adoption

Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.
Panel on Dietetic Products, Nutrition and Allergies
nda [at]
EFSA Journal 2011;9(4):2047
On request from
European Commission